Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05971940 · ClinicalTrials.gov registry record · Phase 3
A Study of Orforglipron (LY3502970) in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone
A Phase 3 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 3
- Development phase
- 559
- Enrollment target
NCT05971940 is a Phase 3 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 559 participants.
The verdict
NCT05971940, a Phase 3 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 559 participants
- Enrollment target
Study Summary
The main purpose of this study is to determine safety and efficacy of orforglipron compared with placebo in adult participants with type 2 diabetes and inadequate glycemic control with diet and exercise alone. The study will last approximately 54 weeks.
Interventions
- DRUG Placebo
- DRUG Orforglipron
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 559 participants |
| Start Date | 2023-08-09 |
| Est. Completion | 2025-04-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05971940
The ClinicalTrials.gov registry entry for NCT05971940 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 559 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05971940 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05971940 about?
NCT05971940 is a clinical study titled "A Study of Orforglipron (LY3502970) in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone". The main purpose of this study is to determine safety and efficacy of orforglipron compared with placebo in adult participants with type 2 diabetes and inadequate glycemic control with diet and exercise alone. The study will last approximately 54 weeks.
What is the current status of trial NCT05971940?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 559 participants. The study started on 2023-08-09. Estimated completion is 2025-04-03.
What interventions are being tested in trial NCT05971940?
The interventions under investigation include: Placebo (DRUG), Orforglipron (DRUG).
Who is sponsoring clinical trial NCT05971940?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.